Fenn C. Mathew

Array ( [id] => 6886759 [patent_doc_number] => 20010020028 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2001-09-06 [patent_title] => 'Agents for treating neurodegenerative disorders' [patent_app_type] => new [patent_app_number] => 09/778662 [patent_app_country] => US [patent_app_date] => 2001-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10090 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0020/20010020028.pdf [firstpage_image] =>[orig_patent_app_number] => 09778662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1601342 [patent_doc_number] => 06476078 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2002-11-05 [patent_title] => 'Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction' [patent_app_type] => B2 [patent_app_number] => 09/770663 [patent_app_country] => US [patent_app_date] => 2001-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18344 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/476/06476078.pdf [firstpage_image] =>[orig_patent_app_number] => 09770663 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6899981 [patent_doc_number] => 20010009657 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2001-07-26 [patent_title] => 'Determining effects of external stimuli on the brain using PET' [patent_app_type] => new [patent_app_number] => 09/764013 [patent_app_country] => US [patent_app_date] => 2001-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 6115 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0009/20010009657.pdf [firstpage_image] =>[orig_patent_app_number] => 09764013 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1548724 [patent_doc_number] => 06346282 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-02-12 [patent_title] => 'Neuroprotective composition for the prevention and/or treatment of nervous and behavioural alterations due to anxiety states or depression, comprising acetyl-L-carnitine and hypericin' [patent_app_type] => B1 [patent_app_number] => 09/719551 [patent_app_country] => US [patent_app_date] => 2000-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3385 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/346/06346282.pdf [firstpage_image] =>[orig_patent_app_number] => 09719551 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1602788 [patent_doc_number] => 06432967 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-08-13 [patent_title] => 'Enema and enterically-coated oral dosage forms of azathioprine' [patent_app_type] => B1 [patent_app_number] => 09/819051 [patent_app_country] => US [patent_app_date] => 2000-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4085 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/432/06432967.pdf [firstpage_image] =>[orig_patent_app_number] => 09819051 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1566667 [patent_doc_number] => 06376478 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-04-23 [patent_title] => 'Pharmaceutical compositions and methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors' [patent_app_type] => B1 [patent_app_number] => 09/741169 [patent_app_country] => US [patent_app_date] => 2000-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13939 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/376/06376478.pdf [firstpage_image] =>[orig_patent_app_number] => 09741169 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1566869 [patent_doc_number] => 06376508 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-04-23 [patent_title] => 'Treatments for spinal muscular atrophy' [patent_app_type] => B1 [patent_app_number] => 09/735766 [patent_app_country] => US [patent_app_date] => 2000-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 10848 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/376/06376508.pdf [firstpage_image] =>[orig_patent_app_number] => 09735766 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7636989 [patent_doc_number] => 06379666 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-04-30 [patent_title] => 'TNF inhibitors for the treatment of neurological, retinal and muscular disorders' [patent_app_type] => B1 [patent_app_number] => 09/666068 [patent_app_country] => US [patent_app_date] => 2000-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6154 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/379/06379666.pdf [firstpage_image] =>[orig_patent_app_number] => 09666068 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6880463 [patent_doc_number] => 20010031750 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2001-10-18 [patent_title] => 'Isoform specific inhibition for treatment of pain and reduction of anesthetic threshold' [patent_app_type] => new [patent_app_number] => 09/731876 [patent_app_country] => US [patent_app_date] => 2000-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 8467 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0031/20010031750.pdf [firstpage_image] =>[orig_patent_app_number] => 09731876 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1561913 [patent_doc_number] => 06362226 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-03-26 [patent_title] => 'Modulation of in vivo glutamine and glycine levels in the treatment of autism' [patent_app_type] => B1 [patent_app_number] => 09/729881 [patent_app_country] => US [patent_app_date] => 2000-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5773 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/362/06362226.pdf [firstpage_image] =>[orig_patent_app_number] => 09729881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1356012 [patent_doc_number] => 06576636 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2003-06-10 [patent_title] => 'Method of treating a liver disorder with fatty acid-antiviral agent conjugates' [patent_app_type] => B2 [patent_app_number] => 09/730450 [patent_app_country] => US [patent_app_date] => 2000-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 27 [patent_no_of_words] => 16176 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/576/06576636.pdf [firstpage_image] =>[orig_patent_app_number] => 09730450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1441342 [patent_doc_number] => 06335372 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-01-01 [patent_title] => 'Treatment of obsessive compulsive disorder' [patent_app_type] => B1 [patent_app_number] => 09/722263 [patent_app_country] => US [patent_app_date] => 2000-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 806 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/335/06335372.pdf [firstpage_image] =>[orig_patent_app_number] => 09722263 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1441337 [patent_doc_number] => 06335371 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-01-01 [patent_title] => 'Method for inducing cognition enhancement' [patent_app_type] => B1 [patent_app_number] => 09/722262 [patent_app_country] => US [patent_app_date] => 2000-11-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1278 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/335/06335371.pdf [firstpage_image] =>[orig_patent_app_number] => 09722262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1462922 [patent_doc_number] => 06350768 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-02-26 [patent_title] => 'Combination of riluzole and of gabapentin and its use as a medicament' [patent_app_type] => B1 [patent_app_number] => 09/718543 [patent_app_country] => US [patent_app_date] => 2000-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2167 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/350/06350768.pdf [firstpage_image] =>[orig_patent_app_number] => 09718543 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1586465 [patent_doc_number] => 06359010 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-03-19 [patent_title] => 'Methods of treating anxiety and mood disorders with oleamide' [patent_app_type] => B1 [patent_app_number] => 09/718639 [patent_app_country] => US [patent_app_date] => 2000-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 3546 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/359/06359010.pdf [firstpage_image] =>[orig_patent_app_number] => 09718639 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4305163 [patent_doc_number] => 06326362 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-12-04 [patent_title] => '(-)-phosphonorisperidone and (-)-sulforisperidone compositions and methods' [patent_app_type] => 1 [patent_app_number] => 9/700621 [patent_app_country] => US [patent_app_date] => 2000-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3362 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/326/06326362.pdf [firstpage_image] =>[orig_patent_app_number] => 700621 [rel_patent_id] =>[rel_patent_doc_number] =>)